A rapid response of lung squamous cell carcinoma following treatment with sintilimab combined with recombinant humane endostatin injection and nab-paclitaxel in an elderly patient
| Autor: | Junfeng Shi, Yue-Yu Fang, Yi Chen, Hui Sun, Lianhua Ji, Nanyuan Jiang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Percutaneous Lung Neoplasms programmed death 1 inhibitor Paclitaxel Pleural effusion Biopsy Antineoplastic Agents Chest pain Antibodies Monoclonal Humanized Pulmonary vein Albumins Antineoplastic Combined Chemotherapy Protocols medicine lung squamous cell carcinoma Humans Clinical Case Report Lung Tumor marker Aged Neoplasm Staging sintilimab medicine.diagnostic_test endostar recombinant humane endostatin injection business.industry General Medicine medicine.disease Recombinant Proteins Endostatins Tumor Burden Pleural Effusion medicine.anatomical_structure Treatment Outcome Carcinoma Squamous Cell Radiology medicine.symptom Endostatin business Tomography X-Ray Computed Research Article |
| Zdroj: | Medicine |
| ISSN: | 1536-5964 0025-7974 |
| Popis: | Rationale: At present, the prognosis of patients with giant lung squamous cell carcinoma (LSCC) is poor, and there is no safe and effective treatment for elderly patients with large LSCC. Patient concerns: Here, we reported a 77-year-old man admitted to the hospital with cough for 3 months and significant chest pain. Computed tomography (CT) imaging showed a large mass in the left lung with pleural effusion. Diagnoses: Chest CT scan revealed a 12.5 cm × 7.3 cm mass in the left upper lobe adjacent to the pulmonary vein, with left pleural effusion. Pulmonary tumor markers were significantly elevated, and CT-guided percutaneous lung mass biopsy specimens showed LSCC. Interventions: After diagnosis, the patient was treated with sintilimab combined with endostar and nab-paclitaxel. After 2 cycles of treatment, the lung mass in the patient shrank rapidly and the clinical symptoms were relieved. Outcomes: The patient's tumor dramatically shrank, and the pleural effusion was decreased after 4 cycles of treatment without any adverse effects. Meanwhile, the high-level tumor marker resumed normal. Lessons: Sintilimab combined with endostar and nab-paclitaxel may be a good treatment option for lung squamous cell cancer, especially for that in elderly patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|